Launch trends for Incivek and Victrelis in hepatitis C sector

9 August 2011

Results from a survey fielded one month after the launch of Vertex’ (Nasdaq: VRTX) Incivek (telaprevir) and Merck & Co’s (NYSE: MRK) Victrelis (boceprevir) indicate that there is a high demand for triple therapy with the new protease inhibitors in patients with hepatitis C (HCV). Both drugs gained US approval earlier this year, and Victrelis has been cleared in Europe with Incivek gaining a positive opinion (The Pharma Letters passim).

In a new report titled LaunchTrends Incivek and Victrelis, BioTrends, a Decision Resources unit, surveyed a total of 80 physicians (gastroenterologists, hepatologists and infectious disease specialists) about their current perceptions, early experience and anticipated future use of these products. In addition, feedback around patient type, product satisfaction, obstacles to use and promotional activities by Merck and partner Roche and Vertex is captured.

More than half of physicians have initiated trials

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK